The wide spread of coronavirus disease 2019 (COVID-19) has declared a global health emergency. As one of the most important targets for antibody and drug developments, Spike RBD-ACE2 interface has received extensive attention. Here, using molecular dynamics simulations, we explicitly evaluated the binding energetic features of the RBD-ACE2 complex of both SARS-CoV and SARS-CoV-2 to find the key residues. Although the overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, the difference in binding affinity is as large as -16.35 kcal/mol. Energy decomposition analyses identified three binding patches in the SARS-CoV-2 RBD and eleven key residues (Phe486, Tyr505, Asn501, Tyr489, Gln493, Leu455 and etc) which are believed to be the main targets for drug development. The dominating forces are from van der Waals attractions and dehydration of these residues. It is also worth mention that we found seven mutational sites (Lys417, Leu455, Ala475, Gly476, Glu484, Gln498 and Val503) on SARS-CoV-2 which unexpectedly weakened the RBD-ACE2 binding. Very interestingly, the most repulsive residue at the RBD-ACE2 interface (E484), is found to be mutated in the latest UK variant, B1.1.7, cause complete virus neutralization escapes from highly neutralizing COVID-19 convalescent plasma. Our present results indicate that at least from the energetic point of view such E484 mutation may have beneficial effects on ACE2 binding. The present study provides a systematical understanding, from the energetic point of view, of the binding features of SARS-CoV-2 RBD with ACE2 acceptor. We hope that the present findings of three binding patches, key attracting residues and unexpected mutational sites can provide insights to the design of SARS-CoV-2 drugs and identification of cross-active antibodies.
تحميل البحث